文献速递头颈部肿瘤放疗

头颈癌放化疗期间的光生物调节:对黏膜炎、体重下降及喂养管依赖的影响

Photobiomodulation During Chemoradiation for Head and Neck Cancer: Effect on Mucositis, Weight Loss, and Feeding Tube Dependence.
PubMed 文献 · Adv Radiat Oncol · 2023-03-10

该研究回顾性分析了2015至2021年间接受放化疗或放疗的44例头颈癌患者(光生物调节组22例,对照组22例),比较两组最大黏膜炎分级、体重下降及治疗开始后100天喂养管依赖情况。光生物调节组中位最大黏膜炎分级为1级,对照组为3级(P < .0001);光生物调节组发生更高黏膜炎分级的校正比值比为0.024%(P < .0001;95%CI 0.004-0.135)。作者认为光生物调节可能有助于减少头颈癌放化疗相关并发症,主要是黏膜炎严重程度。

要点

  • 光生物调节组中位最大黏膜炎分级为1级,对照组为3级(P < .0001)。
  • 光生物调节组发生更高黏膜炎分级的校正比值比为0.024%(95%CI 0.004-0.135;P < .0001)。
  • 作者认为光生物调节可能有助于减少头颈癌放化疗相关并发症,主要是黏膜炎严重程度。

核心结论

  • 作者认为光生物调节可能有助于减少头颈癌放疗和放化疗相关并发症,主要是黏膜炎严重程度。

研究设计与样本

  • 回顾性病历审查,纳入2015至2021年接受放化疗或放疗的44例头颈癌患者(光生物调节组22例,对照组22例;中位年龄63.5岁,范围45-83岁)。

主要发现

  • 光生物调节组中位放疗剂量为60 Gy,对照组为66 Gy。
  • 光生物调节组11例接受放化疗,11例接受单纯放疗(中位光生物调节治疗22次,范围6-32次);对照组16例接受放化疗,6例接受单纯放疗。
  • 光生物调节组中位最大黏膜炎分级为1级,对照组为3级(P < .0001)。
  • 光生物调节组发生更高黏膜炎分级的校正比值比为0.024%(P < .0001;95%CI 0.004-0.135),对照组为参照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The standard therapeutic approach in head and neck cancer (HNC) involves multimodality therapy, including surgery, radiation therapy (RT), or chemoradiation therapy (CRT). Treatment complications (mucositis, weight loss, and feeding tube dependence [FTD]) can result in treatment delays, incomplete treatment, and decreased quality of life. Studies on photobiomodulation (PBM) have shown promising reductions in mucositis severity but with little quantitative supporting data. We compared complications for patients with HNC receiving PBM with those in patients who did not, hypothesizing that PBM improves mucositis severity, weight loss, and FTD. METHODS AND MATERIALS: Medical records of 44 patients with HNC treated with CRT or RT from 2015 to 2021 were reviewed (22 PBM, 22 controls; median age, 63.5 years; range, 45-83 years). Between-group outcomes of interest included maximum mucositis grade, weight loss, and FTD 100 days after initiation of treatment. RESULTS: Median RT doses were 60 Gy (PBM) and 66 Gy (control). Eleven patients treated with PBM received CRT; 11 received RT alone (median of 22 PBM sessions [range, 6-32]). Sixteen control group patients received CRT; 6 received RT alone. Median maximal mucositis grades were 1 in the PBM group and 3 in the control group (P < .0001). The adjusted odds of higher mucositis grade were only 0.024% (P < .0001; 95% confidence interval, 0.004-0.135) in PBM compared with the control group. CONCLUSIONS: PBM may have a role in decreasing complications related to RT and CRT for HNC, mainly mucositis severity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Krc RF, Singh SA, Fang W, et al. Photobiomodulation During Chemoradiation for Head and Neck Cancer: Effect on Mucositis, Weight Loss, and Feeding Tube Dependence. Adv Radiat Oncol. 2023. PMID: 37213482. doi:10.1016/j.adro.2023.101216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。